Evidence map›Paper›PMID 41078145›Full record

ArticleJournal of clinical pharmacology2026

A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Posdinemab (JNJ-63733657) in Healthy Chinese Adults.

Fangfang Wang, Juanfang Liu, Daisy Bai, Lingjue Li, Maggie Fedgchin, David Henley, Haiyan Li, Fan Zhang

2 registry-linked trialsAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03375697 phase1completednot on this map

A 2-Part Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease

TypeinterventionalSponsorJanssen Research & Development, LLCRan2017 to 2019Enrolled72ConditionsAlzheimer DiseaseArmsJNJ-63733657, Placebo
NCT03689153 phase1completednot on this map

A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Japanese Subjects

TypeinterventionalSponsorJanssen Pharmaceutical K.K.Ran2018 to 2019Enrolled24ConditionsHealthyArmsJNJ-63733657, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fangfang WangState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
Juanfang LiuJohnson & Johnson, Shanghai, China.
Daisy BaiJohnson & Johnson, Shanghai, China.
Lingjue LiJohnson & Johnson, Titusville, NJ, USA.
Maggie FedgchinJohnson & Johnson, Titusville, NJ, USA.
David HenleyJohnson & Johnson, Titusville, NJ, USA.
Haiyan LiState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, China.
Fan ZhangJohnson & Johnson, Shanghai, China.

Funding

Johnson & Johnson
6 · The paper itself

Abstract

Posdinemab, a humanized immunoglobulin G1/κ monoclonal antibody, binds with high affinity to phosphorylated tau protein which is associated with Alzheimer's disease (AD) pathophysiology. Posdinemab reduced tau seeding in murine models and was well tolerated in Phase-1 clinical studies. This open-label, single-arm, Phase-1 study examined the effects of posdinemab with single intravenous dose (60 mg/kg) in healthy adults from China. The main objectives were to assess posdinemab serum pharmacokinetics (PK, primary), safety and tolerability (secondary), and presence of anti-drug antibodies (ADAs; secondary). Results were compared with Phase-1 European first-in-human (NCT03375697) and Japanese (NCT03689153) studies. Healthy Chinese participants (N = 10), mean age 60.0 (SD 3.80) years and 60% female, received posdinemab. Mean posdinemab serum C

Indexed as

Antibodies, Monoclonal, HumanizedAdultArea Under CurveChinaEast Asian PeopleFemaleHealthy VolunteersHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAlzheimer's diseaseanti‐drug antibodiesChinesemonoclonal antibodypharmacokineticstau

Identifiers

PMID41078145
PMCPMC12859175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.